[go: up one dir, main page]

UY29857A1 - DERIVATIVES OF 4-AMINO-QUINAZOLINA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS. - Google Patents

DERIVATIVES OF 4-AMINO-QUINAZOLINA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS.

Info

Publication number
UY29857A1
UY29857A1 UY29857A UY29857A UY29857A1 UY 29857 A1 UY29857 A1 UY 29857A1 UY 29857 A UY29857 A UY 29857A UY 29857 A UY29857 A UY 29857A UY 29857 A1 UY29857 A1 UY 29857A1
Authority
UY
Uruguay
Prior art keywords
therapeutics
derivatives
amino
preparation
application
Prior art date
Application number
UY29857A
Other languages
Spanish (es)
Inventor
Thomas Anne
Despeyroux Pierre
Gilles Courtemanche
Geslin Michel
Augereau Jean Michel
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36645639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29857(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY29857A1 publication Critical patent/UY29857A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a derivados de la 4-amino-quinazolina, de fórmula general (I), en forma de base o de sal de adición a un ácido, así como en forma de hidrato o de solvato. Procedimiento de preparación y aplicación en terapéutica.The invention relates to derivatives of 4-amino-quinazoline, of the general formula (I), in the form of a base or salt addition to an acid, as well as in the form of hydrate or solvate. Procedure of preparation and application in therapeutics.

UY29857A 2005-10-12 2006-10-12 DERIVATIVES OF 4-AMINO-QUINAZOLINA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS. UY29857A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0510409A FR2891829A1 (en) 2005-10-12 2005-10-12 4-AMINO-QUINAZOLINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF

Publications (1)

Publication Number Publication Date
UY29857A1 true UY29857A1 (en) 2007-05-31

Family

ID=36645639

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29857A UY29857A1 (en) 2005-10-12 2006-10-12 DERIVATIVES OF 4-AMINO-QUINAZOLINA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS.

Country Status (5)

Country Link
AR (1) AR056688A1 (en)
FR (1) FR2891829A1 (en)
TW (1) TW200732308A (en)
UY (1) UY29857A1 (en)
WO (1) WO2007042669A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2061767B1 (en) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
EP2300456A1 (en) 2008-05-22 2011-03-30 Allergan, Inc. Bicyclic compounds having activity at the cxcr4 receptor
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CN102482312A (en) 2009-08-26 2012-05-30 赛诺菲 Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2683705B1 (en) 2011-03-08 2015-04-22 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP3302057A4 (en) * 2015-06-04 2018-11-21 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
KR102419524B1 (en) 2016-03-16 2022-07-08 쿠라 온콜로지, 인크. Cross-linked bicyclic inhibitors of menin-MLL and methods of use
EP3429591B1 (en) 2016-03-16 2023-03-15 Kura Oncology, Inc. Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (en) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 Substituted MENIN-MLL inhibitor and method of use
JP2024545511A (en) * 2021-12-09 2024-12-09 バラ セラピューティクス，インコーポレイテッド Inhibitors of menin-mll interaction

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984001151A1 (en) * 1982-09-24 1984-03-29 Beecham Group Plc Amino-azabicycloalkyl derivatives as dopamine antagonists
GB2295387A (en) * 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
WO2003028641A2 (en) * 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Mch receptor antagonists
US6921821B2 (en) * 2002-06-12 2005-07-26 Abbott Laboratories Antagonists of melanin concentrating hormone receptor
EP1572212A2 (en) * 2002-12-11 2005-09-14 7TM Pharma A/S Quinoline compounds for use in mch receptor related disorders
CL2004000409A1 (en) * 2003-03-03 2005-01-07 Vertex Pharma COMPOUNDS DERIVED FROM 2- (REPLACED CILO) -1- (AMINO OR REPLACED OXI) -CHINAZOLINE, INHIBITORS OF IONIC SODIUM AND CALCIUM VOLTAGE DEPENDENTS; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF ACUTE PAIN, CHRONIC, NEU
EP1844023A1 (en) * 2004-12-31 2007-10-17 Sk Chemicals Co., Ltd. Quinazoline derivatives for the treatment and prevention of diabetes and obesity

Also Published As

Publication number Publication date
WO2007042669A2 (en) 2007-04-19
TW200732308A (en) 2007-09-01
FR2891829A1 (en) 2007-04-13
AR056688A1 (en) 2007-10-17
WO2007042669A3 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
UY29857A1 (en) DERIVATIVES OF 4-AMINO-QUINAZOLINA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS.
UY30115A1 (en) DERIVATIVES OF SULFONAMIDS, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
EA200970149A1 (en) DERIVATIVES N- (AMINOHETEROARIL) -1H-INDOL-2-CARBOXAMIDES, THEIR RECEIVING AND THEIR APPLICATION IN THERAPY
UY28855A1 (en) DERIVATIVES OF 1-AMINO-FTALAZINA ITS PREPARATION AND ITS USE IN THERAPY
UY29047A1 (en) DERIVATIVES OF SULFONAMIDS, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
CY1109911T1 (en) PYRROLOVENZODIAZEPINES
NO20080129L (en) Process for the preparation of dihydroquinazolines
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
EA201070786A1 (en) BENZOFUROPYRIMIDINONES
EA201170703A1 (en) Derivatives of Adamantylbenzamide
EA201070424A1 (en) HINAZOLINDION DERIVATIVES, THEIR OBTAINING AND THEIR APPLICATION IN THERAPY
UA96994C2 (en) Derivatives of 7-alkynyl-1,8-naphthyridones, method of the preparation and use thereof
ECSP11011224A (en) DERIVATIVES OF TIADIAZOLES AND OXADIAZOLS, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY
ATE466570T1 (en) AQUEOUS HFSH FORMULATION
MX372721B (en) HALOGENATED ANALOGUES OF ANTIFIBROTIC AGENTS.
ATE504556T1 (en) PRODUCTION OF SODIUM DIFORMIATE
UY29690A1 (en) DERIVATIVES OF N- (HETEROARIL) -1-HETEROARILALQUIL-1H-INDOL-2-CARBOXAMIDES, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS.
ATE553106T1 (en) HETEROARYLPYRROLOPYRIDINONES AS KINASE INHIBITORS
UA104420C2 (en) Use of glutaric acid derivatives or the pharmaceutically acceptable salts thereof as anti-arrhythmic agents
UY29518A1 (en) DERIVATIVES OF RENT-, ALQUENIL- AND ALQUINILCARBAMATOS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS.
MX2009000768A (en) Macrocyclic lactams.
UY29859A1 (en) DERIVATIVES OF 1-AMINO-ISIQUINOLINE, ITS PREPARATION AND THERAPEUTIC APPLICATION
CR9565A (en) DERIVATIVES OF 4,5-DIARILPIRROL, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
UY32496A (en) DERIVATIVES OF N - [(6-AZA-BICYCLE [3.2.1] OCT-5-IL) -ARIL-METHYL) -HETEROBENZAMIDE, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS.
EA200801366A1 (en) DERIVATIVES 3,6-DIGIDRO-2-OXO-6N-1,3,4-TIADIAZINA

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120515